Antibody neutralizing human respiratory syncytial virus
The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.
1. A method of preventing or treating an RSV infection in an elderly human subject, comprising administering to the subject an effective amount of an antibody or antigen binding fragment that binds to human RSV F protein, wherein the antibody or antigen binding fragment comprises a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:1, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:4, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:6.
2. The method of claim 1 , wherein the antibody or antigen binding fragment comprises a heavy chain variable domain having the amino acid sequence of SEQ ID NO:8 and a light chain variable domain having the amino acid sequence of SEQ ID NO:9.
3. The method of claim 1 , wherein the antibody or antigen binding fragment comprises a heavy chain variable domain having the amino acid sequence of SEQ ID NO:8 and a light chain variable domain having the amino acid sequence of SEQ ID NO:7.
4. The method of claim 1 , wherein the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO:23 and a light chain having the amino acid sequence of SEQ ID NO:25.
5. The method of claim 1 , wherein the method further includes administering to the subject an antibody or an antigen binding fragment thereof against a respiratory pathogen selected from influenza, human cytomegalovirus (hCMV), human metapneumovirus (hMPV), human parainfluenza (hPIV), human rhinovirus (hRV), Mycoplasma pneumonia, Streptococcus pneumoniae , adenovirus, bocavirus, enterovirus, norovirus, or BK virus.
6. The method of claim 5 , wherein the respiratory pathogen is influenza, hCMV, hMPV, hPIV, norovirus, or BK virus.
7. The method of claim 2 , wherein the method further includes administering to the subject an antibody or an antigen binding fragment thereof against a respiratory pathogen selected from influenza, human cytomegalovirus (hCMV), human metapneumovirus (hMPV), human parainfluenza (hPIV), human rhinovirus (hRV), Mycoplasma pneumonia, Streptococcus pneumoniae , adenovirus, bocavirus, enterovirus, norovirus, or BK virus.
8. The method of claim 7 , wherein the respiratory pathogen is influenza, hCMV, hMPV, hPIV, norovirus, or BK virus.
9. The method of claim 3 , wherein the method further includes administering to the subject an antibody or an antigen binding fragment thereof against a respiratory pathogen selected from influenza, human cytomegalovirus (hCMV), human metapneumovirus (hMPV), human parainfluenza (hPIV), human rhinovirus (hRV), Mycoplasma pneumonia, Streptococcus pneumoniae , adenovirus, bocavirus, enterovirus, norovirus, or BK virus.
10. The method of claim 9 , wherein the respiratory pathogen is influenza, hCMV, hMPV, hPIV, norovirus, or BK virus.
11. The method of claim 4 , wherein the method further includes administering to the subject an antibody or an antigen binding fragment thereof against a respiratory pathogen selected from influenza, human cytomegalovirus (hCMV), human metapneumovirus (hMPV), human parainfluenza (hPIV), human rhinovirus (hRV), Mycoplasma pneumonia, Streptococcus pneumoniae , adenovirus, bocavirus, enterovirus, norovirus, or BK virus.
12. The method of claim 11 , wherein the respiratory pathogen is influenza, hCMV, hMPV, hPIV, norovirus, or BK virus.
13. The method of claim 1 , wherein the antibody or antigen binding fragment that binds to human RSV F protein is provided in an immunogenic composition comprising an antigen selected from RSV F protein and RSV G protein and fragments thereof.
14. The method of claim 2 , wherein the antibody or antigen binding fragment that binds to human RSV F protein is provided in an immunogenic composition comprising an antigen selected from RSV F protein and RSV G protein and fragments thereof.
15. The method of claim 3 , wherein the antibody or antigen binding fragment that binds to human RSV F protein is provided in an immunogenic composition comprising an antigen selected from RSV F protein and RSV G protein and fragments thereof.
16. The method of claim 4 , wherein the antibody or antigen binding fragment that binds to human RSV F protein is provided in an immunogenic composition comprising an antigen selected from RSV F protein and RSV G protein and fragments thereof.